Business Context and Reporting Period
Ultragenyx Pharmaceutical Inc. filed this Form 8-K on August 10, 2015, reporting the entry into a material definitive agreement. The filing details the First Amendment to a Collaboration and License Agreement originally dated September 30, 2010, between Ultragenyx and Nobelpharma Co., Ltd.
Key Financial Metrics
This filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses exclusively on the terms of a contractual amendment regarding supply arrangements and royalty rates.
Material Changes Versus Prior Period
- Supply Arrangements: The amendment establishes that Ultragenyx shall supply Product to Nobelpharma and Nobelpharma shall supply Drug Substance to Ultragenyx under future negotiated agreements. Both parties retain the right to source these items from third parties or manufacture them internally.
- Termination Provisions: New clauses require Ultragenyx to use Commercially Reasonable Efforts to fulfill reasonable orders during a notice period if terminating supply, and to provide technical data for production transfer upon termination.
- Royalty Reductions: The royalty rate payable by Ultragenyx to Nobelpharma has been reduced from high-single digits to mid-single digits in the United States and lower mid-single digits in other UPI Territory countries. Further reductions to lower mid-single digits in the U.S. may apply under certain circumstances.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance, management commentary on future performance, or a discussion of general risks. The primary contingency noted is the requirement for both parties to use Commercially Reasonable Efforts to manufacture and supply products until new supply agreements are finalized.
Key Facts for Investor Verification
- Confirmation of the specific "mid-single digit" and "lower mid-single digit" royalty percentages defined in the amended agreement.
- Timeline for the negotiation and execution of the new supply agreements for Product and Drug Substance.
- Impact of the royalty reduction on Ultragenyx's future cost of goods sold and gross margins.
- Details regarding the "certain circumstances" that would trigger an additional royalty reduction in the United States.